Pharming Group to Post FY2022 Earnings of $0.04 Per Share, Oppenheimer Forecasts (NASDAQ:PHAR)
Pharming Group to Post FY2022 Earnings of $0.04 Per Share, Oppenheimer Forecasts (NASDAQ:PHAR)
Pharming Group (NASDAQ:PHAR – Get Rating) – Oppenheimer issued their FY2022 earnings estimates for shares of Pharming Group in a note issued to investors on Sunday, October 30th. Oppenheimer analyst H. Singh anticipates that the company will post earnings per share of $0.04 for the year. The consensus estimate for Pharming Group's current full-year earnings is $0.03 per share. Oppenheimer also issued estimates for Pharming Group's Q4 2022 earnings at $0.00 EPS and FY2024 earnings at $0.03 EPS.
輝瑞集團(納斯達克：PharGet評級)-奧本海默在10月30日(星期日)發給投資者的一份報告中發佈了他們對Pharming Group股票2022財年的收益預期。奧本海默分析師H·辛格預計，該公司今年的每股收益將達到0.04美元。對Pharming Group目前全年收益的普遍預期為每股0.03美元。奧本海默還發布了對Pharming Group 2022年第四季度每股收益為0.00美元和2024財年每股收益為0.03美元的預期。
Separately, TheStreet upgraded shares of Pharming Group from a "d+" rating to a "c" rating in a report on Monday, August 15th.
另外，華爾街在8月15日週一的一份報告中將Pharming Group的股票評級從“d+”上調至“c”。
Pharming Group Stock Performance
輝瑞集團股票表現
Pharming Group (NASDAQ:PHAR – Get Rating) last announced its earnings results on Thursday, August 4th. The company reported $0.04 EPS for the quarter, topping the consensus estimate of $0.01 by $0.03. The firm had revenue of $50.15 million for the quarter, compared to the consensus estimate of $51.99 million. Pharming Group had a net margin of 14.90% and a return on equity of 8.98%.
輝瑞集團(納斯達克：PharGet Rating)最近一次公佈財報是在8月4日(星期四)。該公司公佈本季度每股收益為0.04美元，比普遍預期的0.01美元高出0.03美元。該公司本季度營收為5015萬美元，而市場普遍預期為5199萬美元。輝瑞集團的淨利潤率為14.90%，股本回報率為8.98%。
About Pharming Group
關於Pharming Group
(Get Rating)
(獲取評級)
Pharming Group N.V., a biopharmaceutical company, develops and commercialize protein replacement therapies and precision medicines for the treatment of rare diseases and unmet medical needs in the United States, Europe, and internationally. The company's lead product is Ruconest, a recombinant human C1 esterase inhibitor that is used for the treatment of acute hereditary angioedema.
生物製藥公司Pharing Group N.V.開發蛋白質替代療法和精準藥物並將其商業化，用於治療美國、歐洲和國際上未得到滿足的罕見疾病和醫療需求。該公司的主導產品是Ruconest，一種用於治療急性遺傳性血管性水腫的重組人C1酯酶抑制劑。
Featured Articles
專題文章
- Get a free copy of the StockNews.com research report on Pharming Group (PHAR)
- New Revenue Strategy, Strong Earnings, Apple Remains a Buy
- Chesapeake Energy Focus on Natural Gas Leads to Strong Results
- Devon Energy Lower After Beating Q3 Views But Slashing Dividend
- Are Investors Bailing on Travel America as Diesel Shortages Loom?
- Sell-Side Interest Drives Mondelez Higher
- 免費獲取StockNews.com關於Pharming Group的研究報告(Phar)
- 新的收入戰略，強勁的收益，蘋果仍然是一個買入者
- 切薩皮克能源專注於天然氣帶來強勁業績
- Devon Energy股價下跌，此前第三季度業績好於預期，但大幅削減股息
- 柴油短缺迫在眉睫，投資者是否放棄了美國之旅？
- 賣方興趣推動Mondelez走高
Receive News & Ratings for Pharming Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pharming Group and related companies with MarketBeat.com's FREE daily email newsletter.
接受Pharming Group Daily的新聞和評級-在下面輸入您的電子郵件地址，通過MarketBeat.com的免費每日電子郵件時事通訊接收對Pharming Group和相關公司的最新新聞和分析師評級的每日簡要摘要。
譯文內容由第三人軟體翻譯。